◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2159

Mediwelcome Healthcare Management & Technology Inc. (2159) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Health Information Services · DATA UPDATED 2026-08-11

Mediwelcome Healthcare Management & Technology Inc. (2159) operates in the Health Information Services industry and is headquartered in Beijing, China with about 150 employees. Its market capitalization is roughly CNY 470 million. In the fiscal year ended 2025-12-31, 2159 reported CNY 468M in revenue and CNY 10M in net income.

Mediwelcome Healthcare Management & Technology Inc., an investment holding company, provides integrated healthcare marketing solutions in the People's Republic of China.

Interactive charts & full statements →

2159 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 468MCNY 322MCNY 331MCNY 323M
Gross ProfitCNY 95MCNY 51MCNY 30MCNY 33M
Operating Income (EBIT)CNY 2M(CNY 34M)(CNY 73M)(CNY 91M)
Net IncomeCNY 10M(CNY 45M)(CNY 94M)(CNY 89M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2159 Free Cash Flow History

2159 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 190MCNY 194MCNY 214MCNY 318M
Total LiabilitiesCNY 85MCNY 121MCNY 94MCNY 117M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2159 viewer.

Other Companies in Health Information Services

← 2158All “0-9” companies2160 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.